NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.
about
Emerging preclinical pharmacological targets for Parkinson's diseaseNeuroprotective Transcription Factors in Animal Models of Parkinson DiseaseMaintenance of postmitotic neuronal cell identityRole of Nuclear Receptors in Central Nervous System Development and Associated DiseasesNuclear receptors in neurodegenerative diseases.Correlation between orphan nuclear receptor Nurr1 expression and amyloid deposition in 5XFAD mice, an animal model of Alzheimer's disease.A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C).Insights from cerebellar transcriptomic analysis into the pathogenesis of ataxia.Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease.Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.Primary culture of mouse dopaminergic neurons.Nurr1-Based Therapies for Parkinson's Disease.Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.Upregulation of Glutaredoxin-1 Activates Microglia and Promotes Neurodegeneration: Implications for Parkinson's DiseasemiRNAs as novel therapeutic targets and diagnostic biomarkers for Parkinson's disease: a patent evaluation of WO2014018650.Production of Nurr-1 Specific Polyclonal Antibodies Free of Cross-reactivity Against Its Close Homologs, Nor1 and Nur77.Ligand Dependent Switch from RXR Homo- to RXR-NURR1 Heterodimerization.LIM kinases: cofilin and beyond.An update on potential therapeutic strategies for Parkinson's disease based on pathogenic mechanisms.Admixing of MPTP-Resistant and Susceptible Mice Strains Augments Nigrostriatal Neuronal Correlates to Resist MPTP-Induced Neurodegeneration.Make dopamine neurons great again: An exciting new therapeutic option in parkinson's disease.Toward neuroprotective treatments of Parkinson's disease.Impact of Pitx3 gene knockdown on glial cell line-derived neurotrophic factor transcriptional activity in dopaminergic neurons.Vitamin C-Induced Epigenetic Modifications in Donor NSCs Establish Midbrain Marker Expressions Critical for Cell-Based Therapy in Parkinson's Disease.Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits.Cografting astrocytes improves cell therapeutic outcomes in a Parkinson's disease model.Localization of nuclear receptor subfamily 4, group A, member 3 (NR4A3) in Lewy body disease and multiple system atrophy.Serotonin neuron development: shaping molecular and structural identities.LIN28A enhances the therapeutic potential of cultured neural stem cells in a Parkinson's disease model.Distinct roles of hand2 in developing and adult autonomic neurons.Molecular characterization and analysis of the porcine NURR1 gene.Environmental Enrichment Prevents Transcriptional Disturbances Induced by Alpha-Synuclein Overexpression.
P2860
Q26764724-2B268CF9-B591-4567-BB77-48B98845A6B3Q26765693-EA94F62A-D969-450F-BB28-D5EB7CCE8189Q27010931-2B1A5CA9-C5C4-4E56-99AD-50734EB81C53Q27025212-F0071939-3BE9-474F-9B03-26A73A1FCD64Q34580020-2CEFC1DE-D7A6-4673-A8D4-DD771B648C2AQ34995704-C1BAF643-8B34-472B-9B32-84A54E8C89A7Q35224798-D9FE3512-178D-4E10-A567-F7CC86B26A93Q35747030-FAB6235D-32EE-4263-8FED-C11CDEC5EA7DQ35822548-B65D23B1-03F0-40C1-809C-3507356610D0Q35999331-757F9EAA-A781-47B7-9EA6-E3D2D0607A08Q36788096-B5152E67-2461-4B45-923B-F86457921DE5Q36803630-5FF4F79C-5B5D-4793-BFB2-0D870EF62489Q36925905-CD8675A9-E62E-4A4F-9824-C17B45377B03Q37523363-D2AA4A3D-9A0F-465E-8490-2FD886ABE112Q38259297-539C81D6-188A-4934-9197-3DD2BFD1C9C0Q38422888-CE0FCFAA-E79B-4B41-B9D3-D9114B4A013DQ38686743-82B3EE68-81FE-41F3-9405-1EB670C1ACAEQ38818738-0DD41809-ABCE-42D3-83D1-0FB6A5EF148CQ38823785-B8997A1D-E53E-44DF-B9EF-FAE2BCDBB103Q39298090-1F30F1EE-3ECB-4567-B7D4-040709F8B984Q39385540-A9A29E81-435E-4951-9151-9BA8FE83170CQ41896366-8080BFF1-B075-491C-B098-DFA228F6908FQ42361834-B5EFF0E0-DB0F-4C7B-A864-98D2977672F1Q42376392-4FCC8F17-A0FF-4244-BF50-26944737503FQ46362244-760C42E0-A316-45F3-8627-4BD6A8829CD4Q47262338-A29DB951-F1BA-435D-BCFE-E3D4DCD3055DQ47924415-FBFEFD42-A4EA-4C8F-A73E-EB62D39B56E5Q48000070-8E32F60A-FF49-4B3A-9DF8-B2B423DB9530Q48563911-3FE9933E-D5CD-4166-841E-74FA2839C664Q48946221-D2BF469C-D1F0-4050-B989-959B563B0C3BQ53060332-AFBD29CD-9BDF-45DE-9772-2770C20E7A62Q54942969-C686A9A9-B71C-4D33-B972-11987E2D8393
P2860
NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.
@ast
NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.
@en
type
label
NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.
@ast
NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.
@en
prefLabel
NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.
@ast
NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.
@en
P2093
P2860
P1476
NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.
@en
P2093
Mickael Decressac
Nikolaos Volakakis
Thomas Perlmann
P2860
P2888
P304
P356
10.1038/NRNEUROL.2013.209
P407
P577
2013-10-15T00:00:00Z